REDX PHARMA LIMITED

("Redx" or the "Company")

Update to Year-End Date

Alderley Park, UK, 19 December 2025 Redx Pharma, the clinical-stage, biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease announces a change to its accounting reference date and financial year-end from 30 September to 31 December, with immediate effect.

As a result of this change, Redx is expected to file 15-month audited accounts with Companies House by the end of September 2026. It is expected that the Company will provide shareholders with an operational update during H1 2026.

A copy of all Company announcements can be found at: https://www.redxpharma.com/news-events/

For further information, please contact:

Redx Pharma Limited

UK Headquarters

Caitlin Pearson, Head of Communications

ir@redxpharma.com

T: +44 (0)1625 469 918

FTI Consulting

Simon Conway/ Ciara Martin

T: +44 (0)203 727 1000

About Redx Pharma Limited

Redx Pharma is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicine for the treatment of fibrotic disease. Pioneering the next generation of anti-fibrotic medicines, the Company is currently progressing RXC008, a first-in-class GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease through the clinic and has completed a Phase 2a program in idiopathic pulmonary fibrosis (IPF) with zelasudil, a potential best-in-class selective ROCK2 inhibitor.

Additionally, the Company has an early-stage discoidin domain receptor inhibitor program with potential to be a first-in-class approach for chronic kidney disease. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage assets and discovery pipeline, but also by its strategic transactions including with AstraZeneca and Jazz Pharmaceuticals, as well as the sale of pirtobrutinib (RXC005, LOXO-305) to Loxo Oncology (Eli Lilly). Pirtobrutinib, the only approved non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, has transitioned quickly from FDA approval in the US, to broader international approvals.